TP53 and myelodysplastic syndrome: A similar algorithm was recently created from 1471 MDS patients, incorporating the standard prognostic variables (karyotype, platelet count, hemoglobin, bone marrow blast percentage, age) and seven discrete genetic mutations (TP53, STAG2, RUNX1, RAD21, SRSF2, ASXL1, and SF3B1) that had independent impact on overall and leukemic free survival [30].